PLB985_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
AML · Acute Myeloid Leukemia
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
- subtype
- —
- cancer_type
- AML
- ccle_sample_id
- PLB985_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
- synthetic_from_ccle
- true
- display_name
- PLB-985
- ccle_lineage
- blood
- ccle_lineage_subtype
- AML
- oncotree_code
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.366
- CHOLESTEROL_HOMEOSTASIS+0.358
- INFLAMMATORY_RESPONSE+0.296
- TNFA_SIGNALING_VIA_NFKB+0.161
- MYC_TARGETS_V2+0.142
- KRAS_SIGNALING_UP+0.125
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.100
- IL6_JAK_STAT3_SIGNALING+0.070
- HYPOXIA+0.063
- COMPLEMENT-0.036
Top 10 suppressed
- MITOTIC_SPINDLE-0.741
- PROTEIN_SECRETION-0.740
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.619
- UV_RESPONSE_DN-0.556
- G2M_CHECKPOINT-0.548
- E2F_TARGETS-0.525
- APICAL_JUNCTION-0.515
- TGF_BETA_SIGNALING-0.511
- COAGULATION-0.494
- NOTCH_SIGNALING-0.457
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MOLM6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.846 |
| 2 | ME1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.813 |
| 3 | OCIAML3_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.777 |
| 4 | HL60_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.749 |
| 5 | EOL1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.724 |
| 6 | PL21_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.712 |
| 7 | 0b5850f2-648a-4dad-a48d-82150c12acb4 | — | — | 0.702 |
| 8 | 289b3dee-bd46-4286-8e7b-86ffb573d37e | — | — | 0.695 |
| 9 | OCIAML5_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.679 |
| 10 | TCGA-CV-A45W-01A-11R-A24Z-07 | — | — | 0.674 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.366 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.358 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.296 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.161 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.142 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.125 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.070 | Inavolisib | — uncovered |
| HYPOXIA | 0.063 | Idelalisib | — uncovered |